Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521339 · ClinicalTrials.gov registry record · Phase 2
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00521339 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 31 participants.
The verdict
NCT00521339, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
Interventions
- DRUG Apremilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-08-01 |
| Est. Completion | 2009-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521339
The ClinicalTrials.gov registry entry for NCT00521339 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Apremilast is the first listed.
NCT00521339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521339 about?
NCT00521339 is a clinical study titled "Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis". The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
What is the current status of trial NCT00521339?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2007-08-01. Estimated completion is 2009-05-01.
What interventions are being tested in trial NCT00521339?
The interventions under investigation include: Apremilast (DRUG).
Who is sponsoring clinical trial NCT00521339?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.